高级检索
赵伟, 白霜, 康艳丽, 吕敏, 王建, 李琴, 吴疆, 郑群. B群流行性脑脊髓膜炎疫苗研究进展[J]. 中国公共卫生, 2022, 38(8): 1088-1092. DOI: 10.11847/zgggws1137414
引用本文: 赵伟, 白霜, 康艳丽, 吕敏, 王建, 李琴, 吴疆, 郑群. B群流行性脑脊髓膜炎疫苗研究进展[J]. 中国公共卫生, 2022, 38(8): 1088-1092. DOI: 10.11847/zgggws1137414
ZHAO Wei, BAI Shuang, KANG Yan-li, . Development of group B meningococcal vaccine: a progress review[J]. Chinese Journal of Public Health, 2022, 38(8): 1088-1092. DOI: 10.11847/zgggws1137414
Citation: ZHAO Wei, BAI Shuang, KANG Yan-li, . Development of group B meningococcal vaccine: a progress review[J]. Chinese Journal of Public Health, 2022, 38(8): 1088-1092. DOI: 10.11847/zgggws1137414

B群流行性脑脊髓膜炎疫苗研究进展

Development of group B meningococcal vaccine: a progress review

  • 摘要: 流行性脑脊髓膜炎(流脑)是由脑膜炎奈瑟菌感染引起的以脑脊髓膜炎和菌血症为主的呼吸道传染病,由于缺乏有效的预防手段,B血清群已经成为流脑主要的流行菌群之一。近年来,反向疫苗学技术的出现极大地推动了B群流脑疫苗的研究工作,疫苗的研制也取得了突破性进展,为研究出更为有效的流脑疫苗,本文对B群流脑疫苗领域中新型蛋白抗原疫苗、外膜囊泡疫苗和重组蛋白疫苗等方面的研究进展进行了综述。

     

    Abstract: Epidemic cerebrospinal meningitis is a respiratory infectious disease caused by Neisseria meningitidis, most commonly manifesting as meningitis and septicaemia. Due to the lack of effective prevention measures, serogroup B Neisseria meningitidis (MenB) has become one of dominant epidemic bacterial groups. In recent years, the emergence of reverse vaccinology has greatly promoted the research on serogroup B meningococcal vaccine, and researches on the vaccine have also made a breakthrough. In order to develop a more effective meningococcal vaccine, this article reviews the research progress on new protein antigen vaccine, outer membrane vesicle vaccine and recombinant protein vaccine in the field of MenB vaccine.

     

/

返回文章
返回